These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 7333766

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Current concepts of the role of aluminum in chronic kidney failure patients].
    Gruev I, Belovezhdov N.
    Vutr Boles; 1983; 22(2):1-4. PubMed ID: 6362201
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Treatment of dialysis encephalopathy with deferoxamine].
    Starkstein S, Berthier M, Nogués M, Leiguarda R.
    Medicina (B Aires); 1986; 46(3):327-31. PubMed ID: 3574092
    [No Abstract] [Full Text] [Related]

  • 6. [Prolonged and reversible encephalopathy in a chronic haemodialysis patient. Probable responsibility of aluminium salts (author's transl)].
    Buge A, Poisson M, Masson S, Bleibel JM, Lafforgue B, Raymond P, Jaudon MC.
    Nouv Presse Med; 1978 Jun 10; 7(23):2053-9. PubMed ID: 673773
    [Abstract] [Full Text] [Related]

  • 7. Whole body aluminium in chronic renal failure and dialysis encephalopathy.
    Williams ED, Elliott HL, Boddy K, Haywood JK, Henderson IS, Harvey I, Kennedy AC.
    Clin Nephrol; 1980 Oct 10; 14(4):198-200. PubMed ID: 6775855
    [Abstract] [Full Text] [Related]

  • 8. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST, Pedersen FB.
    Nephrol Dial Transplant; 1989 Oct 10; 4(7):676. PubMed ID: 2510071
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reversible dialysis encephalopathy: role for aluminium-containing gels.
    Masselot JP, Adhemar JP, Jaudon MC, Kleinknecht D, Galli A.
    Lancet; 1989 Oct 10; 2(8104-5):1386-7. PubMed ID: 82892
    [No Abstract] [Full Text] [Related]

  • 14. [The causes of aluminum cumulation and poisoning in patients with chronic kidney failure treated by hemodialysis on a regular program and the possibilities for therapy].
    Válek A, Sulková S, Laurinová Z.
    Ter Arkh; 1991 Oct 10; 63(6):89-93. PubMed ID: 1948757
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
    Mudde AH, Roodvoets AP, Van Groningen K.
    Neth J Med; 1985 Oct 10; 28(1):6-11. PubMed ID: 3974771
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.